Brief: Cerevel Therapeutics Announces Positive Results In Emraclidine Ambulatory Blood Pressure Monitoring Trial

Cerevel Therapeutics Holdings

19/12/2022 11:43

Dec 19 (Reuters) - Cerevel Therapeutics Holdings Inc
 CERE.O :
    * CEREVEL THERAPEUTICS ANNOUNCES POSITIVE RESULTS IN
EMRACLIDINE
AMBULATORY BLOOD PRESSURE MONITORING TRIAL
    * CEREVEL THERAPEUTICS HOLDINGS INC - DATA PROVIDE CLEAR
EVIDENCE
EMRACLIDINE DOES NOT INDUCE INCREASE IN BLOOD PRESSURE WITH
CHRONIC DOSING IN PEOPLE LIVING WITH SCHIZOPHRENIA
    * CEREVEL THERAPEUTICS HOLDINGS INC - EMRACLIDINE WAS
GENERALLY
WELL-TOLERATED, WITH A SIDE EFFECT PROFILE CONSISTENT WITH PRIOR
TRIALS
    * CEREVEL THERAPEUTICS HOLDINGS INC - COMPREHENSIVE PHASE 2
PROGRAM IN SCHIZOPHRENIA ON TRACK TO READ OUT IN 1H 2024

Source text for Eikon:  ID:nGNX6mgyPC 
Further company coverage:  CERE.O 
 ((Reuters.Briefs@thomsonreuters.com;))